However, to our knowledge, there have been no reports of autologous peripheral blood stem cell transplantation (aPBSCT) for adult eosinophilic granuloma. We describe a patient in whom aPBSCT was performed for disseminated, refractory eosinophilic granuloma.
A 34-year-old woman was admitted to our hospital with high fever and general fatigue. She had lymphadenomegaly and a 4-week history of pain in the lumbosacral region. There were no motor or sensory deficits in the lower limbs, no parasethesia, and no bladder or bowel problems. Blood cell counts and serum chemistry including calcium, phosphate, and alkaline phosphatase were normal. However, levels of serum immunoglobulin G and soluble interleukin-2 receptor were elevated (Figure 1 ). An increase was also noted in the proportion of eosinophils in the bone marrow (Figure 2a ). Magnetic resonance imaging revealed an iliac bone tumor and marrow signal changes (hypointense on T1-weighted). A bone scan revealed an increased radiotrace uptake over the iliac lesion. Computed tomographyguided biopsy was performed on the iliac bone tumor. 
Histological examination revealed features of eosinophilic granuloma, with aggregates of Langerhans' histiocytes (Figures 2b and c) . The patient was treated with low-grade radiotherapy and chemotherapy several times. In September 2003, a cystic lesion of the thyroid gland appeared (Figures 1 and 2d) . In July 2004, a cystic lesion was found in the right lung (Figures 1 and 2e) . In March 2005, a compression fracture of the vertebral body occurred (Figures 1 and 2f) . In May 2006, mobilization chemotherapy with cyclophosphamide 1300 mg/day (day 1), vincristine 2.0 mg/day (day 1), and etoposide 250 mg/day (days 1, 2, 3 and 4) 1-4 days was given on successive days, followed by G-CSF (filgrastim, 450 mg/day subcutaneously) for 9 days, beginning on day 5. More than 11.4 Â 10 6 peripheral CD34 þ cells per kilogram of body weight (b.w.) were harvested on day 14 (Figure 1 ). In July 2006, ranimustine 400 mg/day (day À7), etoposide 300 mg/day and cytarabine 640 mg/day (from day À6 to day À3), and melphalan 230 mg/day (day À2) were given, followed by infusion of 7.55/kg b.w. CD34 þ autologous stem cells. The post transplant course was uneventful, with a neutropenic episode lasting six days. G-CSF (filgrastim) 450 mg/day was instituted from day þ 7 to day þ 9. Leukocyte (41000/ml) and platelet engraftment (420 000/ml) occurred at day þ 9. After aPBSCT, her high fever and some abnormalities of the laboratory data such as CRP, sIL-2R, and IgG disappeared, and these conditions were maintained for 10 months (Figure 1) . LCH is a rare disorder with variable clinical manifestations. 2 A definitive diagnosis of LCH is made by histopathological evidence of Birbeck granules and immunohistochemical detection of S-100 and CD1a antigens in the tissue samples. 2 In the present case, histological examination also revealed positive staining for CD1a and S-100 protein. LCH may sometimes result in life-threatening multisystem diseases. This depends on the involvement of 'risk organ' (that is, hematopoietic system, liver, spleen, and lungs). 5 Thus, the present case was thought to be highrisk LCH, since she manifested abnormalities of the hematopoietic system and lungs. Various treatments have been employed for LCH, but not always with successful outcomes. Some authors recommend conservative treatment with biopsy and immobilization and the use of steroids. 6 Although patients with localized disease may have an excellent outcome with minimal or no treatment, a significant proportion of patients with disseminated disease may undergo progression to a fatal outcome despite chemotherapy 5 and immunotherapy. 6 Since LCH derives from hyperactivation and proliferation of macrophage progeny cells, there is a rationale for the use of allogeneic BMT in treating advanced, high-risk or resistant LCH. 7, 8 In particular, the successful allogeneic BMT performed by Ringden et al. 8 casts new light on LCH patients failing other therapeutic approaches. 5, 8, 9 In contrast, autologous marrow rescue has been considered a less attractive option due to the inherent tendency of the marrow to give rise to LCH. However, a case of effective autologous BMT for LCH is also reported, although it is a rare case. 4 In addition, in most of the pediatric patients, myeloablative high-dose regimens are associated with a high treatmentrelated morbidity and mortality, and mobilizing stem cells from pediatric patients may be difficult. 4, 9 In our patient, some risk factors for LCH resolved after aPBSCT and she maintained complete remission for 10 months, having never previously experienced such a stable period. Thus, aPBSCT performed for LCH can be considered as a second treatment choice for patients with no acceptable donor. 
